Company intelligence / Profile preview

Healthcann

Ownership: Private
Development stage: Preclinical

Overview

Healthcann develops proprietary drug delivery technologies to improve the absorption and convenience of cannabinoid-based therapeutics. Their lead platform, AdvanDrop, enables rapid onset and flexible administration of cannabinoids such as CBD and THC. Preliminary preclinical studies show faster effect compared to standard oils. The company aims to introduce pharmaceutical raw materials based on this technology into pharmacies in Poland and expand internationally as regulations allow.

Therapeutic areas: Other
Modalities: Cannabinoidsdrug delivery systems
Industry: Biotech

Drug pipeline

2 assets

AdvanDrop Bev

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Healthcann.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Healthcann.

Explore the full profile